<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: K-Ras <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> are a strong predictive biomarker for resistance to epidermal growth factor receptor (EGFR) inhibitors in patients with colorectal and <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We previously showed that the novel Toll-like receptor 9 (TLR9) <z:chebi fb="4" ids="48705">agonist</z:chebi> immunomodulatory oligonucleotide (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMO</z:e>) has a strong in vivo activity in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> models by interfering with EGFR-related signaling and synergizing with the anti-EGFR monoclonal antibody cetuximab </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: In the present study, we investigated, both in vitro and in vivo, the antitumor effect of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMO</z:e> alone or in combination with cetuximab in subcutaneous colon and orthotopic <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> models harboring K-Ras mutations and resistance to EGFR inhibitors </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: We showed that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMO</z:e> was able to significantly restore the sensitivity of K-Ras mutant <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells to cetuximab, producing a marked inhibition of cell survival and a complete suppression of <z:chebi fb="0" ids="52290">mitogen</z:chebi>-activated protein kinase phosphorylation, when used in combination with cetuximab </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMO</z:e> interfered with EGFR-dependent signaling, modulating the functional interaction between TLR9 and EGFR </plain></SENT>
<SENT sid="5" pm="."><plain>In vivo, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMO</z:e> plus cetuximab combination caused a potent and long-lasting cooperative antitumor activity in LS174T <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and in orthotopic AsPC1 <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The capability of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMO</z:e> to restore cetuximab sensitivity was further confirmed by using K-Ras mutant <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell models obtained through homologous recombination technology </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: We showed that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMO</z:e> markedly inhibits growth of K-Ras mutant colon and <z:hpo ids='HP_0002894'>pancreatic cancers</z:hpo> in vitro and in <z:mp ids='MP_0003815'>nude</z:mp> mice and cooperates with cetuximab via multiple mechanisms of action </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, we propose <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMO</z:e> plus cetuximab as a therapeutic strategy for K-Ras <z:mp ids='MP_0002169'>wild-type</z:mp> as well for K-Ras mutant, cetuximab-resistant colorectal and <z:hpo ids='HP_0002894'>pancreatic cancers</z:hpo> </plain></SENT>
</text></document>